In-depth Analysis and Forecast Of The Osteoarthritis Market 2024 On The Global As Well As Regional Level
"The
Latest Research Report OpportunityAnalyzer: Osteoarthritis -
Opportunity Analysis and Forecasts to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About Osteoarthritis
Market
Osteoarthritis (OA) is a slowly
progressive joint disease that is typically seen in middle-aged to
elderly people. The disease is caused by the breakdown of the joint
cartilage due to mechanical stress or biochemical alterations, which
causes the bone underneath to fail. OA can occur together with other
types of arthritis, such as gout or rheumatoid arthritis (RA). OA
tends to affect commonly used joints such as the hands and spine as
well as the weight-bearing joints such as the hips and knees. The
causes of OA are not fully understood. However, genetic factors, and
damage to the joints, either through repeated excessive loading and
stress of a joint over time (for example, the knee joint in an obese
person) or by injury (such as a break or dislocation of a finger
joint) increases the risk of developing OA. There is no single test
to diagnose OA. Several methods are used to diagnose OA and to rule
out other problems: medical history, physical exam, X-rays, blood
tests, or joint fluid analysis. The structural changes that occur
with old age may not be accompanied by symptoms, which makes the
estimation of the prevalence of OA difficult.
Scope
- Overview of OA, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized OA therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2015 and forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the OA
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global OA therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/879202
Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology
21
3.1.1 Etiology 21
3.1.2 Pathophysiology 24
3.2 Symptoms 26
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities
28
4.3 Global and Historical Trends
30
4.3.1 Total Prevalence of OA - 7MM
30
4.3.2 Diagnosed Prevalence of OA -
7MM 30
4.3.3 US 31
4.3.4 5EU 31
4.3.5 Japan 32
4.4 Forecast Methodology 34
4.4.1 Sources Used 42
4.4.2 Sources Not Used 47
4.4.3 Forecast Assumptions and
Methods 48
4.5 Epidemiological Forecast for
OA (2014-2024) 53
4.5.1 Total Prevalent Cases 53
4.5.2 Diagnosed Prevalent Cases 70
4.5.3 Severity of Knee OA Based on
KL Grades 86
4.6 Discussion 87
4.6.1 Epidemiological Forecast
Insight 87
4.6.2 Limitations of the Analysis
88
4.6.3 Strengths of the Analysis 89
5 Current Treatment Options 90
5.1 Overview 90
5.2 Product Profiles - Major
Therapies 92
5.2.1 NSAIDs (Numerous Branded and
Generic Products) 92
5.2.2 Topical Therapies (Numerous
Branded and Generic Products) 96
5.2.3 Opioids (Numerous Branded
and Generic Products) 101
5.2.4 Antidepressants (Numerous
Branded and Generic Products) 106
5.2.5 Intra-Articular
Corticosteroid Injections (Numerous Branded and Generic Products) 108
6 Unmet Needs Assessment and
Opportunity Analysis 112
6.1 Overview 112
6.2 Analgesic Drugs that
Adequately Address Pain 113
6.2.1 Unmet Need 113
6.2.2 Gap Analysis 114
6.2.3 Opportunity 114
6.3 Disease-Modifying Drugs 115
6.3.1 Unmet Need 115
6.3.2 Gap Analysis 116
6.3.3 Opportunity 116
6.4 Drugs with Improved
Tolerability for Use in the Elderly Patient Population 116
6.4.1 Unmet Need 116
6.4.2 Gap Analysis 117
6.4.3 Opportunity 117
6.5 Improved Implementation of
Guidelines on Non-pharmaceutical Treatments 117
6.5.1 Unmet Need 117
6.5.2 Gap Analysis 118
6.5.3 Opportunity 119
6.6 Early Detection and
Intervention 119
6.6.1 Unmet Need 119
6.6.2 Gap Analysis 120
6.6.3 Opportunity 120
7 Research and Development
Strategies 121
7.1 Overview 121
7.2 Development of Pharmacological
Treatments with Novel MOAs 121
7.3 Development of
Disease-Modifying OA Drugs 122
7.4 Strategic Partnerships 123
7.5 Current Clinical Trial Design
124
7.5.1 Limitations of
Patient-Reported Outcomes 125
7.5.2 Lack of Useful
Subpopulations for Targeted Therapies 125
7.5.3 Lack of Consensus on DMOAD
Trial Design 126
7.6 Future Clinical Trial Design
127
7.6.1 Sensitive Measurement Tools
for Evaluating Joint Morphology 127
7.6.2 Developing and Qualifying
Biomarkers to Enable DMOADs Development 127
7.6.3 Future Trials Need to Take
into Consideration Joint Tissues Other Than Articular Cartilage 128
Send
An Enquiry Request @
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Promising Drugs in Clinical
Development 130
8.2.1 Ampion 130
8.2.2 NKTR-181 134
8.2.3 FX006 (Zilretta) 137
8.2.4 Anti-NGF 140
8.2.5 Invossa 147
8.2.6 Sprifermin 152
8.3 Innovative Early-Stage
Approaches 156
8.3.1 Targeting Innovative Pain
Signaling Pathways 158
8.3.2 Pro-inflammatory Cytokine
Modulation 159
8.3.3 Growth Factor Therapy 160
8.3.4 Subchondral Bone Remodeling
160
9 Pipeline Valuation Analysis 162
9.1 Clinical Benchmarking of Key
Pipeline Drugs 162
9.2 Commercial Benchmark of Key
Pipeline Drugs 163
9.3 Competitive Assessment 165
9.4 Top-Line 10-Year Forecast 166
9.4.1 US 168
9.4.2 5EU 170
9.4.3 Japan 171
10 Appendix 173
10.1 Bibliography 173
10.2 Abbreviations 188
10.3 Methodology 192
10.4 Forecasting Methodology 192
10.4.1 Diagnosed OA Patients 192
10.4.2 Percent Drug-Treated
Patients 193
10.4.3 Drugs Included in Each
Therapeutic Class 193
10.4.4 Launch and Patent Expiry
Dates 194
10.4.5 General Pricing Assumptions
194
10.4.6 Individual Drug Assumptions
195
10.4.7 Generic Erosion 201
10.4.8 Pricing of Pipeline Agents
201
10.5 Physicians and Specialists
Included in this Study 203
10.6 Primary Research-Prescriber
Survey 204
10.7 About the Authors 205
10.7.1 Author 205
10.7.2 Epidemiologist 205
10.8 About GlobalData 206
10.9 Disclaimer 206
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment